A paradigm for the future?

Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …

Prostate cancer incidence and mortality among men of East Asian ethnicity

Historically there has been a perception that risk for diagnosis with and death from prostate cancer among men of East Asian ethnicity was lower than that among men of European/Caucasian ethnicity. … READ MORE …

The prevalence, incidence, and mortality of specific sets of prostate cancer patients by 2020

A newly published paper in the journal PLoSOne has addressed the future prevalence of various different clinical states of prostate cancer here in the USA, along with the mortality of the men diagnosed with prostate cancer. … READ MORE …

Erectile function prior to prostate cancer treatment: a key to expectation management

The ability to recover good erectile function after treatment for localized prostate cancer is — rather obviously — dependent on the quality of patients’ erectile function prior to any treatment. However, good data on this latter factor is not as well documented as one might like. … READ MORE …

Mental and emotional distress among patients with cancer

A new study just published yesterday in the Journal of Clinical Oncology provides some interesting insights into the risk for various types of mental and emotional distress associated with diagnosis and treatment of cancer among > 2,100 patients with cancer interviewed according to a standardized protocol in Germany. … READ MORE …

Early detection of evident prostate cancer metastasis: perhaps not early enough?

It has long been a tenet of prostate cancer therapy (whether correct or not) that the appearance of evident metastasis (M1 disease) in men with supposedly progressive, micrometastatic (M0) disease is a key event in the management of patients because of the association between evident metastasis and the potential for onset of symptomatic bone disease. … READ MORE …

Prostate cancer prevalence and survivorship issues in 2012

A new article in CA: A Cancer Journal for Clinicians provides updated issues on the numbers of people surviving after a diagnosis of cancer in America, and includes data specific to prostate cancer survival. The full text of this article is available on line. … READ MORE …